Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).

Edoardo FranciniKathryn P GrayWanling XieGrace K ShawLoana ValençaBrandon BernardLaurence AlbigesLauren C HarshmanPhilip W KantoffMary-Ellen TaplinCristopher J Sweeney

Published in: The Prostate (2018)

In our hospital-based registry, time of metastatic presentation and disease volume were prognostic for mHSPC pts treated with ADT. This simple prognostic classification system can aid patient counseling and future trial design.

Keyphrases

prostate cancer
small cell lung cancer
squamous cell carcinoma
case report
clinical trial
randomized controlled trial
phase ii
hepatitis c virus
hiv infected
newly diagnosed